MedPath

Use of phalatrikadi kwatha bhavit Haritaki churna in Diabetes patients

Phase 2/3
Not yet recruiting
Conditions
Type 2 diabetes mellitus without complications. Ayurveda Condition: PRAMEHAH,
Registration Number
CTRI/2025/03/083328
Lead Sponsor
Government Akhandanand Ayurveda College BhadraAhmedabad Gujarat
Brief Summary

The drugs in the trial formulation have been described by Acharya Charak collectively as Phalatrikadi Kwatha having action by their Katu tikta rasa and Ruksha guna which help in the Upshoshana of Sweda, Mala, Kleda along with Shaman of kapha. Deepan and pachan effect of Katu and Tikta rasa will have action upon Dhatvagnimandhya and will help in normalizing the body Metabolism. These drugs are easily available in market and are affordable too. So this combination is selected.

Kasaya Rasa, Ushna and Ruksha Guna are main properties of Haritaki. It acts as Kaphgna,as a cleanser and it also improves digestion. In prameha there is Dusti of Medovaha Srotas and Dhatvagni Mandya. Hence Dravya which is of Ushna and Ruksha Guna with Lekhan and Shoshan properties is required that can cleanse the Medovaha Srotas and to increase Dhatvagni.

So, in reference to this concept Haritaki processed in Phalatrikadi Kwatha for seven times is selected that can sharpen the action of Haritaki with its Rasayana property.



Diagnostic Criteria :

PrabhootavilaMutrara

Pipasadhikya

Kshudhadhikya

Swedadhikya

Nindradhikya

Gala Talu shosha

Kara Padatala Daha

Kara Padarala Supti

Angagandha

Shrama

Tandra

The sample size is 30 patients.

Phalatrikadi Kwatha Bhavit Haritaki Churna will be given in 3gm dose with Madhu for thrice a day.

Study Design is Open labelled Clinical Trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Classical signs and symptoms of Prameha.
  • Fasting plasma glucose 126- 200 mg per dl Post Prandial glucose level 200- 300 mg per dl.
  • Only non-insulin-dependent Type – II Diabetes Mellitus patients will be included.
  • Both newly diagnosed patients on allopathic treatment will be included in this study.
  • The dose of Modern Medicine will be adjusted and tapered during the period of trial as per need.
  • Patients having BMI (Body Mass Index) greter than 25 and lesser than 35 will be taken for the study.
Exclusion Criteria
  • Patient age is below 18 years and above 65 years.
  • Chronic Pancreatitis, Ketoacidosis, and Parkinson’s disease.
  • Patients with other metabolic and endocrinal disorders.
  • BMI less than 25 and more than 35 will be excluded.
  • Fasting plasma glucose level greater than 200 mg per dl & Postprandial glucose level greater than 300 mg per dl will be excluded Patients having any other malignancies or any other systemic or serious illness.
  • Patients with diabetic wounds or ulcers Patients of Diabetes mellitus Type 1 (Juvenile Diabetes) Patients having acute & serious complications of Type 2 Diabetes Mellitus Patients with Coronary artery disease, Peripheral vascular disease & cerebrovascular disease Patients having a history of any major complications of Diabetes like Nephropathy, Retinopathy, Diabetic Foot, etc.
  • Pregnant women Insulin-dependent patients.
  • Otherwhere chronicles like STD, Tuberculosis, etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in laboratorial parameters as well as signs and symptoms of30 days
Sthoola Pramehi (Type II Diabetes Mellitus)30 days
Secondary Outcome Measures
NameTimeMethod
It is expected that the drug will break or eradicate the root cause of the diseaseleading to a permanent cure of Diabetes in Sthoola Pramehi by its Rasayana Properties

Trial Locations

Locations (1)

Government Akhandanand Ayurveda College ,Ahmedabad Gujarat.

🇮🇳

Ahmadabad, GUJARAT, India

Government Akhandanand Ayurveda College ,Ahmedabad Gujarat.
🇮🇳Ahmadabad, GUJARAT, India
Prachi Darji
Principal investigator
06355448209
prachidarji98@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.